To address the growing number of dengue cases, India intends to launch the QDENGA dengue vaccine in 2026.
The vaccine would be produced locally by Hyderabad-based Biological E. Limited in collaboration with Japanese pharmaceutical company Takeda.
The alliance hopes to manufacture around 50 million doses yearly, consistent with the 'Make in India' initiative.
All four dengue virus serotypes (DENV-1 to DENV-4) are protected against by the tetravalent live-attenuated vaccine QDENGA.
For best results, the vaccine must be taken in two doses spaced three months apart.
More than 35 nations, including those in Europe, Asia, and Latin America, have ratified QDENGA.
QDENGA's inclusion in national vaccination programs was made easier by the World Health Organization adding it to its list of prequalified vaccines.
In regions where dengue is highly prevalent, the vaccine is authorized for use in children between the ages of 6 and 16.
Over 230,000 dengue infections and 236 associated deaths were reported in India in 2024, underscoring the critical need for preventative measures.
It is anticipated that the vaccine will dramatically lower hospitalizations and severe instances of dengue, particularly in high-risk areas.
The 'Make in India' campaign may lower vaccine costs and increase accessibility for the Indian populace through local production.
To satisfy demand worldwide, Takeda plans to increase output to 100 million doses per year by 2030.
As of April 2025, clinical studies are being conducted in India to produce local safety data for Takeda's regulatory application for QDENGA.
The successful rollout of QDENGA in India could serve as a model for other countries battling dengue, emphasizing the importance of global collaboration in public health initiatives.